Kalhoff H, Rascher W, Diekmann L, Stock G J, Manz F
Paediatric Clinic, Dortmund, Germany.
Acta Paediatr. 1995 May;84(5):490-4. doi: 10.1111/j.1651-2227.1995.tb13680.x.
Of 452 low-birth-weight infants who were routinely screened for maximum renal acid stimulation (MRAS) (urine pH < 5.4), 149 episodes of incipient late metabolic acidosis (urine pH < 5.4 on 2 consecutive days) were randomly allocated to either a control group or treatment with NaHCO3 or NaCl (2 mmol/kg/day each) for 7 days. Urinary excretion of aldosterone-18-glucuronide (Aldo), arginine vasopressin (AVP) and cortisol was determined in timed urine samples. On day 1, patients with MRAS showed a tendency towards increased urinary excretion of Aldo compared with infants without MRAS. In patients who received alkali therapy, urinary excretion of Aldo, AVP and cortisol decreased or showed a trend to lower values from day 1 to day 7, whereas in patients with MRAS but no specific therapy, Aldo and AVP showed a tendency to increase. We concluded that persistent MRAS is not only characterized by a reduced rate of weight gain and a tendency to decreased nitrogen assimilation, but also increased secretion of Aldo and AVP.
在452例常规接受最大肾酸刺激(MRAS)筛查(尿pH<5.4)的低出生体重儿中,149例初发晚期代谢性酸中毒发作(连续2天尿pH<5.4)被随机分为对照组或接受碳酸氢钠或氯化钠治疗(各2 mmol/kg/天),为期7天。在定时尿样中测定醛固酮-18-葡萄糖醛酸苷(Aldo)、精氨酸加压素(AVP)和皮质醇的尿排泄量。第1天,与无MRAS的婴儿相比,MRAS患儿的Aldo尿排泄量有增加趋势。在接受碱治疗的患者中,从第1天到第7天,Aldo、AVP和皮质醇的尿排泄量减少或呈降低趋势,而在有MRAS但未接受特殊治疗的患者中,Aldo和AVP呈增加趋势。我们得出结论,持续性MRAS不仅表现为体重增加率降低和氮同化减少的趋势,还表现为Aldo和AVP分泌增加。